Literature DB >> 2064311

Antigen variation in a human glioblastoma: from the primary tumor to the second recurrence, permanent cell line and xenotransplantation tumors.

T Bilzer1, D Stavrou, W Wechsler, B Wöhler, E Keiditsch.   

Abstract

Antigen expression in a human glioblastoma was investigated by immunochemical methods in the primary tumor, the first and second recurrence, a permanent cell line derived from the first recurrence and in its xenotransplantation tumors. In the primary tumor, GFAP, vimentin, S100, Leu-7 and glioma-associated antigens (GAA) as defined by the monoclonal antibodies (mAbs) MUC 2-39, MUC 8-22 and MUC 2-63 were markedly expressed. In the recurrences, gradual loss of GFAP and Leu-7 could be observed, whereas S100, vimentin and GAA gave similar results to those in the primary tumor. In contrast, fibronectin and collagen IV, which were restricted to the vessel walls in the primary tumor, were represented in sarcomatous areas of the recurrences. In some of these areas, co-expression of glial cell markers was observed. In short-term cell cultures, expression of glia- and glioma-associated antigens as well as fibronectin and collagen IV was comparable to that of the recurrent tumor tissue. In long-term passages, immunoreactivity of GFAP, Leu-7 and S100 decreased, whereas GAA, vimentin and fibronectin increased. Collagen IV positive cells were not visible beyond passage 15. Transplantation tumors were only partly positive for glial cell markers, but revealed strong immunoreactivity for GAA, fibronectin and collagen IV. With these observations we confirm that the phenotypic variability of glioma cells makes it difficult to identify the origin of cells in human glioblastomas from their antigenicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2064311

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  6 in total

1.  Expression of annexin II in glioma cell lines and in brain tumor biopsies.

Authors:  S J Nygaard; H K Haugland; E K Kristoffersen; M Lund-Johansen; O D Laerum; O B Tysnes
Journal:  J Neurooncol       Date:  1998-05       Impact factor: 4.130

2.  Products of cells from gliomas: IX. Evidence that two fundamentally different mechanisms change extracellular matrix expression by gliomas.

Authors:  P E McKeever; J Varani; S M Papadopoulos; M Wang; J P McCoy
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

3.  Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy.

Authors:  Anne Clavreul; Isabelle Jean; Laurence Preisser; Agnès Chassevent; Anne Sapin; Sophie Michalak; Philippe Menei
Journal:  In Vitro Cell Dev Biol Anim       Date:  2009-06-16       Impact factor: 2.416

Review 4.  A comprehensive profile of recurrent glioblastoma.

Authors:  B Campos; L R Olsen; T Urup; H S Poulsen
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

5.  Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas.

Authors:  A M Yahanda; J M Bruner; L A Donehower; R S Morrison
Journal:  Mol Cell Biol       Date:  1995-08       Impact factor: 4.272

6.  Spontaneous Post-Transplant Disorders in NOD.Cg- Prkdcscid Il2rgtm1Sug/JicTac (NOG) Mice Engrafted with Patient-Derived Metastatic Melanomas.

Authors:  Enrico Radaelli; Els Hermans; Lorna Omodho; Annick Francis; Sara Vander Borght; Jean-Christophe Marine; Joost van den Oord; Frédéric Amant
Journal:  PLoS One       Date:  2015-05-21       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.